Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
| Autor: | Jean-Jacques Garaud, Marc Derive, Xavier Wittebole, François Vandenhende, Thierry Dugernier, Valerie Cuvier, Peter Pickkers, Stephan Witte, Miguel Angel Gomez Sanchez, Margarita Salcedo-Magguilli, Aurelie Olivier, Bruno François, Jean-Paul Mira, Ricard Ferrer, Pierre-François Laterre, Sébastien Gibot |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Population lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] Critical Care and Intensive Care Medicine Placebo Gastroenterology 03 medical and health sciences 0302 clinical medicine Double-Blind Method Pharmacokinetics Internal medicine medicine Animals Humans Immunologic Factors Adverse effect education education.field_of_study business.industry Septic shock 030208 emergency & critical care medicine medicine.disease Shock Septic Clinical trial Treatment Outcome 030228 respiratory system Pharmacodynamics SOFA score business |
| Zdroj: | Intensive Care Medicine, 46, 7, pp. 1425-1437 Intensive Care Medicine, 46, 1425-1437 |
| ISSN: | 0342-4642 |
| DOI: | 10.1007/s00134-020-06109-z |
| Popis: | Contains fulltext : 225478.pdf (Publisher’s version ) (Closed access) PURPOSE: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodynamic parameters in septic shock patients. METHODS: This was a multicenter randomized, double-blind, two-stage study. Patients received either continuous infusion of nangibotide (0.3, 1.0, or 3.0 mg/kg/h) or placebo. Treatment began |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink